Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Aprea Therapeutics, Inc. (APRE)

AIM ImmunoTech Inc. and Aprea Therapeutics, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Aprea Therapeutics, Inc. are of similar size ($6.2M and $6.1M). AIM ImmunoTech Inc. grew revenue faster over the last twelve months: −21.5% against −81.0%. Aprea Therapeutics, Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Aprea Therapeutics, Inc. leads on 10 and AIM ImmunoTech Inc. on 6.

Valuation

Metric AIM APRE Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 97.70 9.40
P/B 0.35 0.82 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 0.65 0.66
EV/Sales (71.38) (34.76) 9.02
Earnings yield (2,575.37%) (134.54%) (32.88%)
Free cash flow yield (533.84%) (45.64%) (23.13%)

Profitability

Metric AIM APRE Biotechnology median
Gross margin (23.16%) 100.00% 68.51%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (62.83%) (51.96%)
Return on assets (169.28%) (53.24%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM APRE Biotechnology median
Revenue growth (TTM) (21.49%) (80.99%) 6.76%
EPS growth (last fiscal year) 72.19% 17.87% 29.88%
Revenue growth, 5-year CAGR (11.60%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM APRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 9.67 4.97
Net debt to EBITDA 0.22 1.11 1.01

Dividend

Metric AIM APRE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM APRE Biotechnology median
Market cap 6.07m 6.24m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack